contractpharmaJune 11, 2020
Tag: Dyadic , COVID-19 vaccine , Frederick National Laboratory
Dyadic International Inc., a global biotechnology company, has been selected by the Frederick National Laboratory to engineer its patented and proprietary C1 cell lines to produce a number of COVID-19 vaccine candidates which will be utilized by the Vaccine Research Center (VRC) part of the National Institute of Allergy and Infectious Diseases (NIAID), at the National Institutes of Health.
"We are proud that our C1 technology has the potential to support the Vaccine Research Center COVID-19 vaccine development program by engineering innovative high yield C1 fungal cell lines to rapidly produce candidate vaccines with increased immunogenicity and attractive manufacturing properties." said Mark Emalfarb, Dyadic's CEO.
Emalfarb also commented, "In addition, we are grateful to be able to also work together with the U.S., EU, Israel, and are in other discussions with governmental agencies, biotech/biopharma companies, and funding organizations to apply our industrially proven hyper productive C1 gene expression platform by helping to address the immediate coronavirus outbreak and be better prepared for future infectious diseases, pandemic, and epidemic outbreaks. We hope to turn this unfortunate situation into an opportunity to advance biopharmaceutical manufacturing to help speed development, lower the cost and improve the performance of biologic vaccines and drugs such as insulin, seasonal flu and other vaccines and antibodies to make healthcare more accessible and affordable to patients globally."
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: